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INTRODUCTION
Lower urinary tract symptoms (LUTS) secondary to benign
prostatic hyperplasia (BPH) are one of the most common dis-
orders in elderly males, and alpha1-blockers are now viewed
as first-line agents for the management of LUTS caused by
BPH. Alpha1-blockers originally were believed to work by
blocking alpha adrenergic receptors found in the prostate and
its capsule, and thereby relaxing stromal smooth muscle (1).
However, this mechanism does not fully account for the long-
term clinical responses observed for these drugs in BPH.
Moreover, recent studies have demonstrated that alpha1-
blockers, such as doxazosin and terazosin, induce apoptosis
of prostate stromal smooth muscle and epithelial cells with-
out affecting cellular proliferation, and have correlated this
with symptom improvement (2-4). It was also found that
the apoptotic effects of doxazosin and terazosin are mediated
by a mechanism involving the quinazoline nucleus and not
one involving alpha1-adrenoceptor blockade, since the non-
quinazoline alpha1-adrenoceptor antagonist tamsulosin does
not elicit an apoptotic response (5).
The apoptosis of prostate tissue induced by alpha1-block-
ers may confer a considerable benefit in BPH, since it could
alter the size and shape of the prostate over time, reduce its
volume, or halt further growth. Moreover, previous studies
have shown that 5alpha reductase inhibitor reduces prostate
size and serum prostate-specific antigen (PSA) levels by induc-
ing apoptosis (6, 7). However, few systematic studies have been
undertaken to test this hypothesis, although some investiga-
tors have reported that alpha1-blockers do not affect serum
PSA concentrations (7, 8). We conducted the present study
to compare the impacts of terazosin and tamsulosin on prostate
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Impacts of the Quinazoline-Based Alpha1-Antagonist, Terazosin, and of
the Sulfonamide Derivative, Tamsulosin, on Serum Prostate-Specific
Antigen and Prostate Volume
The aim of this study was to compare the impacts of terazosin and tamsulosin, on
prostate activity, i.e., serum prostate-specific antigen, total prostate volume (TPV),
and transition zone volume (TZV). A total of 90 patients who presented with lower
urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH),
ranging in age from 52 to 83 yr (median 65 yr), were included in the study. Patients
were given 0.2 mg tamsulosin, 2 mg terazosin, or 4 mg terazosin once daily for an
average of 14 months (range, 6-56 months). Subjective (International Prostate Symp-
tom Scores, I-PSS) and objective (maximal flow rate and post-void residual) param-
eters were assessed both at baseline and at treatment cessation. Serum prostate-
specific antigen (PSA) levels were found to be unaffected by treatment (1.2 and 1.3
ng/mL). In total patients, multivariate analysis showed that baseline TPV was the
only independent predictor of treatment-related TPV reduction. Moreover, baseline
TPV ≥ ≥30 g was found to be associated with a higher likelihood of TPV reduction
(odds ratio [OR], 3.939; 95% confidence interval [CI], 1.506-10.304; p=0.005), and
a baseline TZV of ≥ ≥10 g was associated with a 7.1-times greater chance of TZV
reduction (OR, 7.100; 95% CI, 2.428-20.763; p<0.001). The same model showed
that patients on 2 mg terazosin had a 10.8-fold greater likelihood (OR, 10.770; 95%
CI, 1.409-82.323; p=0.022) and that those on 4 mg terazosin had a 9.0-fold greater
likelihood (OR, 9.001; 95% CI, 1.724-46.995; p=0.009) of a TZV reduction than those
on 0.2 mg tamsulosin. In addition, symptoms improved regardless of prostate activ-
ity after taking alpha1-blockers. Our findings suggest that terazosin reduces TZV
and demonstrate that the relief of symptoms associated with BPH may not be due
to a prostate activity reduction induced by apoptosis in the prostate gland.
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activity. In this study, the serum PSA or prostate volume were
taken to reflect prostate activity. In fact, PSA was used recently
as an indicator of prostate gland activity and function (9-11).
MATERIALS AND METHODS
The clinical records of patients who had presented with
LUTS secondary to BPH between January 2003 and Decem-
ber 2005 were retrospectively reviewed. The study inclusion
criteria were: age ≥50 yr, moderate to severe LUTS (Interna-
tional Prostate Symptom Scores [I-PSS] sum ≥8), and the
ability to communicate, understand, and comply with the
requirements of the study. The exclusion criteria included:
the use of other medications to control bladder symptoms,
the presence of a bladder tumor, bladder stone, or urethral
stricture, neurogenic bladder dysfunction, and restricted
mobility. Patients were also excluded from the analysis if
they had prostate cancer or prostatic intraepithelial neopla-
sia by biopsy, a serum PSA level of >20 ng/mL, a history of
prostate surgery or radiotherapy, an acute urinary retention
or an indwelling catheter, evidence of an acute urinary infec-
tion (pyuria and bacteriuria) on urine analysis, or a medica-
tion history of alpha1-blocker or 5alpha-reductase inhibitor.
Ninety patients met the criteria and constituted the study
cohort. The median (range) age of the study patients was
65.0 (52.0-83.0) yr, their median baseline total prostate vol-
ume (TPV) and transition zone volume (TZV) were 31.5
(17.0-88.0) and 9.6 (2.0- 45.2) mL, respectively, and their
median baseline PSA level was 1.2 (0.2-14.8) ng/mL.
At initial visits, patients underwent a detailed clinical eval-
uation, including a complete history taking, a physical exam-
ination, urinalysis, urine culture, and a digital rectal examina-
tion (DRE). In addition, the followings were measured; PSA
level, prostate volume by transrectal ultrasonography (TRUS),
uroflowmetry, and post-void residual (PVR) urine volume.
I-PSS were also determined. To determine TPV and TZV,
TRUS was performed by a single radiologist using a 7.0 MHz.
transducer (Ultramake-9, ALT Inc., Washington DC, U.S.A.).
Subjects were placed in the left lateral decubitus position
with knees pulled up toward the chest. After DRE, the probe
was inserted and Gray scale ultrasonography was performed.
Anteroposterior (H) and transverse prostate diameters (W)
were measured on largest transverse images. Horizontal dis-
tances between the most proximal and distal prostate bound-
aries on midline sagittal scans were considered to be longitu-
dinal diameters (L). Prostate volumes were estimated assum-
ing an ellipsoid shape using the formula, prostate volume=
/6×H×W×L (12). Patients aged ≥50 yr with suspi-
cious results on DRE and/or a high PSA level (>4 ng/mL)
also underwent a systemic sextant biopsy, under TRUS guid-
ance, using an 18-G needle fitted to an automatic biopsy
gun. Hypoechoic lesions detected by ultrasonography and
areas corresponding to palpable abnormalities on DRE were
also biopsied.
Patients were given 0.2 mg tamsulosin, or 2 mg or 4 mg
terazosin once daily. The median treatment duration was 14.0
(6.0-56.0) months. Uroflowmetry was conducted, with mea-
surements of PVR via abdominal ultrasonography. Maxi-
mum flow rates (Qmax), voided volumes, and PVR were
assessed pre- and post-treatment. Bladder voiding efficiency
(BVE) was defined as voided volume (determined by uro-
flowmetry) divided by initial urine volume (voided volume
plus PVR) (13);
BVE=(voided volume/total bladder capacity)×100
Prostate volume was measured by TRUS at the end of the
treatment period. LUTS and symptom-specific quality of life
(QOL) were assessed using I-PSS and associated QOL index
score pre- and post-treatment.
Survey responses were coded and analyzed using descriptive
statistics, and were reported as medians (25-75th percentiles)
or as numbers and percentages (qualitative variables). For sta-
tistical analysis, patients were categorized according to the med-
ication administered, i.e., ‘0.2 mg tamsulosin’ (n=19) and ‘2
mg terazosin’ (n=16) and ‘4 mg terazosin’ (n=55) or accord-
ing to serum PSA, TPV or TZV reductions. Statistical anal-
ysis was carried out using the Mann-Whitney U test or the
Kruskal-Wallis test for continuous data and the Armitage test
for categorical data. When a significant group difference was
found using the Kruskal-Wallis test, Turkey’s multiple com-
parison test was performed to determine significance.
To identify factors associated with serum PSA, TPV, or TZV
reduction, we calculated odds ratios (ORs) and p values for
trends using univariate and multivariate logistic regression
analyses. Clinical characteristics (age, serum PSA levels, TPV,
TZV, type of alpha1-blockers, and treatment duration) were
individually entered into a univariate model, and variables with
a significance threshold set at p<0.100 were entered into a mul-
tivariate model as dependent variables. In our logistic regres-
sion model, the variables, age, serum PSA, TPV, TZV, and
treatment duration were dichotomized about median values.
The associations between clinical variables and serum PSA,
TPV, and TZV reductions were determined using maximum
likelihood estimates of relative risk with 95% confidence inter-
vals (CIs). CIs were predicated from standard errors of measure-
ment (SEMs) of coefficients, assuming a normal distribution.
A 5% level of significance was used throughout, except as
mentioned above for the univariate logistic regression analysis,
and all statistical tests were two-sided. Statistical analyses were
performed using a commercially available program, SPSS 10.0
(SPSS, Inc., Chicago, IL, U.S.A.).
RESULTS
The baseline and post-treatment group prostate activitiesare shown in Table 1. At baseline, no differences were evident
between the three groups with respect to age, serum PSA, TPV
or TZV, although treatment durations were significantly dif-
ferent (p<0.001). After treatment, groups serum PSA and TZV
values were similar, but TPV was smaller in the 2 mg terazosin
group than that in other two groups (p=0.017). After treat-
ment, 10.5% (2 of 19) in the 0.2 mg tamsulosin group showed
a TZV reduction, whereas 37.5% (6 of 16) in the 2 mg tera-
zosin group and 43.6% in the 4 mg terazosin group showed
a TZV reduction (p=0.010).
Table 2 provides details of outcomes versus changes in pro-
state activity, and shows that I-PSS total scores and QOL index
score decreased regardless of prostate activity after treatment.
However, objective parameters, namely, Qmax, PVR, and
BVE, were not different after treatment, and were at similar
levels in the three groups.
Logistic regression analysis was used to identify predictors
of a prostate activity reduction (univariate analysis failed to
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PSA, prostate-specific antigen; TVP, total prostate volume; TZV, transition zone volume. 
*Kruskal Wallis test. 
a,b,cSuperscript letters indicate significantly different results from each other.
Data presented are medians (25-75th percentiles) or numbers (%).
0.2 mg tamsulosin 2 mg terazosin 4 mg terazosin p value
No. 19 16 55
Age (yr) 63.0 (59.0, 66.0) 66.5 (62.5, 68.0) 65.0 (60.0, 68.0) 0.468*
Medication duration (months) 24.0 (18.0, 33.0)
a 14.5 (11.3, 28.5)
b 12.0 (8.0, 15.0)
c <0.001*
Serum PSA (ng/mL)
Baseline 1.6 (0.9, 2.8) 1.2 (0.7, 2.4) 1.1 (0.7, 2.1) 0.388*
Post-treatment 1.4 (0.8, 2.7) 0.9 (0.7, 2.1) 1.4 (0.9, 26) 0.413*
TPV (mL)
Baseline 31.0 (29.1, 43.8) 31.3 (22.4, 34.4) 33.0 (25.6, 46.3) 0.309*
Post-treatment 34.1 (27.0, 40.8)
a 26.2 (22.7, 30.5)
b 34.0 (26.0, 44.5)
a 0.017*
TZV (mL)
Baseline 10.6 (6.8, 13.7) 7.2 (5.6, 11.6) 10.0 (6.0, 16.0) 0.316*
Post-treatment 14.0 (9.0, 17.6) 10.0 (6.8, 12.2) 11.5 (7.8, 18.3) 0.323*
Table 1. Data at baseline and post-treatment of prostate activity
PSA, prostate-specific antigen; TPV, total prostate volume; TZV, transition zone volume; TZI, transition zone index; I-PSS, International prostate symp-
tom index; QOL, quality of life; Qmax, maximum flow rate; PVR, post-void residual; BVE, bladder voiding efficiency.
*Wilcoxon signed rank test.
Data presented are medians (25-75th percentiles).
PSA TPV TZV
I-PSS total sum
Baseline 14.0 (9.0, 21.0) 14.5 (10.8, 23.0) 15.0 (11.0, 21.0) 14.0 (10.0, 23.0) 14.5 (12.0, 20.3) 15.0 (9.5-23.0)
Post-treatment 9.0 (5.0, 16.5) 9.0 (6.0, 15.0) 10.0 (6.0, 15.0) 9.0 (5.0, 16.0) 8.0 (5.0, 17.0) 11.5 (6.0, 15.0)
p value* <0.001 <0.001 0.001 <0.001 <0.001 <0.001
I-PSS QOL score
Baseline 3.0 (3.0, 4.0) 3.0 (3.0, 4.0)  3.0 (3.0, 4.0) 3.0 (3.0, 5.0) 3.0 (3.0, 4.3) 3.0 (3.0, 4.0)
Post-treatment 3.0 (1.0, 3.0) 2.0 (1.0, 3.0) 3.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.5 (1.0, 3.0)
p value* 0.001 <0.001 0.001 <0.001 0.003 <0.001
Qmax (mL/s)
Baseline 15.5 (11.6, 20.1) 10.3 (7.6, 13.4) 13.4 (8.6, 17.1) 11.1 (7.3, 15.5) 13.0 (7.7, 16.3) 12.1 (7.6, 16.1)
Post-treatment 16.1 (11.4, 20.2) 12.6 (7.4, 16.3) 14.5 (11.1, 17.9) 12.9 (8.9, 16.7) 11.7 (7.5, 18.8) 13.5 (10.2, 16.6)
p value* 0.889 0.140 0.259 0.139 0.175 0.488
PVR (mL)
Baseline 10.0 (0.0, 36.0) 7.0 (0.0, 40.0) 0.0 (0.0, 18.8) 14.5 (0.0, 45.8) 10.0 (0.0, 45.0) 5.0 (0.0, 25.0)
Difference 0.0 (-12.0, 18.0) 0.0 (-15.5, 12.0) 0.0 (-13.0, 23.0) -1.0 (-16.0, 5.0) 0.0 (-12.0, 8.0) 0.0 (-14.5, 17.0)
p value* 0.740 0.475 0.677 0.198 0.559 0.786
BVE (%)
Baseline 95.3 (88.2, 100.0) 94.4 (71.8, 100.0) 100.0 (90.7, 100.0) 92.4 (77.3, 100.0) 94.1 (68.8, 100.0) 95.9 (88.0, 100.0)
Post-treatment 96.2 (86.3, 100.0) 98.9 (88.0, 100.0) 95.5 (87.8, 100.0) 98.9 (87.1, 100.0) 94.8 (86.3, 100.0) 98.7 (87.3, 100.0)
p value* 0.981 0.117 0.931 0.031 0.049 0.852
Table 2. Outcomes according to the changes of prostate activity
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identify any predictor of PSA reduction), and a reduction in
TPV was found to be associated with baseline TPV and the
medication administered. To exclude the possibility of a con-
founding effect, these two variables were subjected to multi-
variate logistic analysis, and baseline TPV was found to be
the only independent predictor of a TPV reduction. Specifi-
cally, a baseline TPV of ≥30 g was found to have an OR of
3.939 for a TPV reduction (95% CI, 1.506-10.304; p=0.005).
On the other hand, univariate analysis indicated the like-
lihood of a TZV reduction was dependent on two factors, i.e.,
baseline TZV and the medication administered, while mul-
tivariate analysis showed that a baseline TZV of ≥10 g was
associated with a 7.1-times greater chance of a TZV reduc-
tion (OR, 7.100; 95% CI, 2.428-20.763; p<0.001). Using
the same model, patients on 2 mg terazosin were found to
have a 10.8-fold greater chance of a TZV reduction (OR,
10.770; 95% CI, 1.409-82.323; p=0.022), and patients on 4
mg terazosin a 9.0-fold greater chance (OR, 9.001; 95% CI,
1.724-46.995; p=0.009) of a TZV reduction than those on
0.2 mg tamsulosin. These results are summarized in Table 3.
DISCUSSION
The prostate is richly innervated with autonomic nerves,
which include both adrenergic and cholinergic fibers. The
prostate expresses four native alpha1-adrenoreceptors, and one
of these, alpha1a, is known to be related to smooth muscle con-
traction (14). Pharmacologic blockade of alpha1-adrenergic
receptors relaxes prostate and bladder neck smooth muscle and
improves the symptoms of BPH, and available data support
the notion that quinazoline alpha1-adrenoceptor antagonists,
such as doxazosin and terazosin, inhibit prostate growth via
smooth muscle cell apoptosis. Moreover, doxazosin and terazosin
are known to induce prostate smooth muscle cell apoptosis via
mechanisms unrelated to alpha1-adrenoceptor blockade (15),
and since smooth muscle represents approximately 40% of
BPH tissue (16), smooth muscle apoptosis and the resulting
stromal regression provide a cellular basis for the therapeutic
effects of an alpha1 blockade.
Transforming growth factor (TGF)-beta1 has potent antipro-
liferative and cytotoxic effects on human benign prostatic ep-
ithelial cells (17). Moreover, recent experimental evidence points
to the deregulation of signal transduction pathways involv-
ing TGF-beta and the disruption of cell attachment to the
extracellular matrix as potential mechanisms that underlies
the apoptotic effect of quinazoline-based alpha1-adrenocep-
tor antagonists on prostate cells (4).
In addition, experimental and clinical evidence indicates
that the induction of prostate smooth muscle cell apoptosis
by doxazosin or terazosin contributes to the long-term improve-
ments observed in LUTS in patients with BPH. In fact, one
study found a direct correlation with borderline significance
(r=0.18, p<0.05) between doxazosin-mediated prostatic smooth
muscle cell apoptosis and the improvement of BPH symptoms
(3). Moreover, this is consistent with the findings of another
study, which demonstrated a direct relationship between clin-
ical response to alpha1-adrenoceptor antagonist therapy and
smooth muscle cell proportion in BPH tissue (18).
Recently, Roehrborn (19) examined whether 3 months of
alfuzosin treatment changes either TPV or TZV, and found
that both were unaffected after 3 months of treatment. Alt-
hough apoptotic induction by alfuzosin was not tested in a
clinical study, its quinazoline structure suggests that it may
induce similar apoptotic effects. However, since 3 months’
treatment with alfuzosin may be a short treatment period to
induce volume changes, additional studies are required to
determine the effect of alpha1-blockers on prostate apoptosis
and volume in patients over longer treatment periods (19).
In the present study, we failed to find any significant treat-
ment-related differences in serum PSA, TPV, and TZV for
0.2 mg tamsulosin, 2 mg terazosin, or 4 mg terazosin. Nev-
ertheless, larger baseline TPV and TZV values were found to
be associated with an increased likelihood of a treatment-relat-
ed TPV or TZV reduction, respectively. Furthermore, terazosin
was found to be more likely to reduce TZV than tamsulosin.
TPV; total prostate volume, TZV; transition zone volume, OR; odds ratio, CI; confidence interval.
TPV TZV
Adjusted OR (95% CI) p value Adjusted OR (95% CI) p value
TPV
Less than 30 g 1.000
30 g or greater 3.939 (1.506-10.304) 0.005
TZV
Less than 10 g 1.000
10 g or greater 7.100 (2.428-20.763) <0.001
Medication
0.2 mg tamsulosin 1.000 1.000
2 mg terazosin 4.078 (0.915-18.186) 0.063 10.770 (1.409-82.323) 0.022
4 mg terazosin 0.930 (0.304-2.842) 0.899 9.001 (1.724-46.995) 0.009
Table 3. Logistic regression anaylsis for reduction of total prostate volume and transition zone volumeImpacts of Terazosin and Tamsulosin on Prostate Activity 513
However, symptom improvement was not found to be asso-
ciated with reduced prostate activity. Our findings suggest
that the quinazoline alpha1-blocker terazosin influences prostate
volume (especially TZV), and demonstrate that relief from
the symptoms of BPH may not be due to prostate volume
reductions induced by alpha1-blockers within the gland. 
In the present study, no prostate tissue biopsy specimens
were obtained, and it is evident that only direct identification
of apoptotic cells in appropriate prostate tissue biopsy samples
is likely to show definitively whether apoptotic induction is
directly associated with serum PSA, prostate volume reduc-
tions, and symptom relief. Although it has been reported
that tamsulosin does not induce prostate cell apoptosis in
vitro (15), prostate tissue from tamsulosin-treated patients
has not been examined for the presence of apoptotic cells
after several months of treatment, which leaves the possibil-
ity open that in vitro and in vivo differences exist (19). More-
over, if tamsulosin does not elicit an apoptotic response,
smooth muscle relaxation alone does not fully account for
its long-term clinical effect. Thus, a study on a larger popu-
lation for a longer period of observation is required to deter-
mine the clinical significances of terazosin and tamsulosin-
induced apoptosis and to characterize their alpha1-depen-
dent and -independent contributions.
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